This statistic shows the number of new drugs receiving approval status in South Korea in 2014, by therapeutic category. In that year, a total of 33 new drugs were approved for use in South Korea, five of which were anti-cancer drugs.
Number of new drugs receiving approval status in South Korea in 2014, by therapeutic category
Profit from additional features by authenticating your Admin account
Please authenticate by going to "My account" → "Administration".
Then you will be able to mark statistics as favourites and use personal statistics alerts.
Statista Accounts:
Access All Statistics. Starting from $468 / Year
Learn more about how Statista can support your business.
Korea Drug Research Association. (July 16, 2016). Number of new drugs receiving approval status in South Korea in 2014, by therapeutic category [Graph]. In Statista. Retrieved January 27, 2022, from https://www.statista.com/statistics/646536/new-drug-approvals-south-korea-by-therapy-area/
Korea Drug Research Association. "Number of new drugs receiving approval status in South Korea in 2014, by therapeutic category ." Chart. July 16, 2016. Statista. Accessed January 27, 2022. https://www.statista.com/statistics/646536/new-drug-approvals-south-korea-by-therapy-area/
Korea Drug Research Association. (2016). Number of new drugs receiving approval status in South Korea in 2014, by therapeutic category . Statista. Statista Inc.. Accessed: January 27, 2022. https://www.statista.com/statistics/646536/new-drug-approvals-south-korea-by-therapy-area/
Korea Drug Research Association. "Number of New Drugs Receiving Approval Status in South Korea in 2014, by Therapeutic Category ." Statista, Statista Inc., 16 Jul 2016, https://www.statista.com/statistics/646536/new-drug-approvals-south-korea-by-therapy-area/
Korea Drug Research Association, Number of new drugs receiving approval status in South Korea in 2014, by therapeutic category Statista, https://www.statista.com/statistics/646536/new-drug-approvals-south-korea-by-therapy-area/ (last visited January 27, 2022)
